AN2 Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
conference. My name is Moritz. Our next presenting company is AN2 Therapeutics, and joining us from AN2 is their CEO, Eric Easom. To begin with, congrats on the IND clearance. For those not familiar with the story of AN2, could you just give us a brief intro into AN2 Therapeutics, your boron chemistry platform, and the programs you currently have in development?
Yeah, no, be happy to. Thank you for having us here. AN2 is a boron chemistry platform company, and we've discovered all of our molecules internally. We have three compounds in clinical development. We have our polycythemia vera, and then we have two other ones, one for Chagas disease and one for non-tuberculous mycobacteria lung disease. We have three that are just starting phase II that we're going to have data readouts, and then we have a bunch of things coming. We just announced last week a program for hypophosphatasia that is going into development that will also start phase I next year, and then a number of other oncology programs behind that. We have a very robust pipeline, I think, that has a lot of value creation potential and addresses a lot of high unmet needs.
We're kind of agnostic to the disease area per se, because we're across now oncology, infectious diseases, bone disease, et cetera. But we follow the biology, basically. Anyway, we're very excited about the potential of all these programs and the future setup for AN2.
Great. Let's start with PV. Your phase II PV trial is about to kick off and has three parts. You'll have a sentinel cohort, followed by an open-label part one, and then a randomized withdrawal, part two. Can you just walk us through the rationale of this particular trial design?
Yeah. For PV, we have lots of clinical observational data showing that our drug lowers hematocrit in a very red blood cell-specific way. It's oral, and so forth. The main question on the table is, does this translate to PV patients? We believe it has a high probability of doing that. The primary purpose of the study initially for the sentinel and then part one is its open label, is to really see that proof of concept and translation in PV patients with this therapeutic. If it does, we're going to feel quite bullish about this. Of course, we haven't dosed a PV patient, so we'll be looking at safety and the amount of efficacy, I think. The other important part is, we know what the dosing curves look like in non-PV patients, but we don't know in PV.
We'll be exploring three different doses to kind of see where we land on the dose curve. That's kind of the part one, but that'll give us high confidence that we have the ability to control hematocrit of patients who have very poor control, less than 50% is kind of the data on that. We think we can really improve upon that. Then the part two is more of just taking drug off and showing, okay, without drug, it clearly goes back to, reverts back to baseline, their kind of baseline status, and we can pick up other PRO activity in a blinded fashion and so forth. That's the main purpose of that. What's not shown there is a part three, which will be a long-term extension, which will be durability over long periods of time, which will be important to gather.
And size-wise, how many patients do you expect to include in each of the parts of your study?
Yeah, the sentinel group is a low-dose run-in of 10 patients into a bigger part one, which is 75 total patients. We plan to take 75 kind of through the whole trial.
Yeah. What is the current status of the sentinel cohort?
When do you plan to dose the first patient?
Soon. We are excited. We just got regulatory clearance from the FDA, we announced, as you mentioned earlier. Also simultaneously, we announced we have Australia and India. We plan to dose the first patient yet this year. I mean, we are going to get started on this and get the show on the road with lots of data and milestone updates throughout 2027.
When are we going to get the first data cut from this?
Yeah, always a big question. All this is, we do not have experience with these sites and PV trials, so it is always how quickly can we get patients enrolled? We think the short answer is, we think the sentinel group will be in the first quarter. That will, but that is mainly just a low dose, but mainly a safety readout to make sure. Also, is there an over-response or a more profound response, let us say, for PV patients than we saw in non-PV patients? So pick up where we are on the dosing curve early, and then we will expand that.
from there. But early, Q1-ish.
You mentioned this is the first time you are testing this drug in PV, but importantly, unlike many other early-stage drugs, your drug already has a very large existing safety database. Can you just give us some color on that? What data have you already collected?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
